Cover Image
市場調查報告書

化療誘發性貧血:流行病學、病患人數的市場預測,治療流程,已上市/開發平台藥物分析

Chemotherapy induced anemia: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis

出版商 Datamonitor Healthcare 商品編碼 365173
出版日期 內容資訊 英文 176 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
化療誘發性貧血:流行病學、病患人數的市場預測,治療流程,已上市/開發平台藥物分析 Chemotherapy induced anemia: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis
出版日期: 2016年04月01日 內容資訊: 英文 176 Pages
簡介

本報告提供化療誘發性貧血 (CIA)的已上市及臨床實驗中 (開發平台上)的治療藥相關分析,各產品的市場規模的估計值,目前癌症治療的發展帶來的影響,及現在被看好的治療藥 (紅血球造血因子製劑 (ESA))的效果與限制,藥物開發的促進、阻礙因子,影響藥物處方的諸要素,今後的市場機會等相關調查。

市場預測:化療誘發性貧血

  • 摘要整理
  • 市場概要與趨勢
  • 市場定義和分析方法
  • Aranesp (darbepoetinα)
  • DexFerrum (鐵聚葡萄糖)
  • Epogen (紅血球生成素α)
  • Feraheme (ferumoxytol)
  • Injectafer (carboxymaltose鐵)
  • NeoRecormon (紅血球生成素β)
  • Venofer (鐵、蔗糖複合物)
  • 一次調查技術

治療方法:化療誘發性貧血

  • 摘要整理
  • 一次調查技術
  • 疾病定義與診斷方法
  • 患者的分類
  • 各國治療系統
  • 目前治療選擇
  • 處方的趨勢
  • 化療誘發性貧血相關的未滿足需求

流行病學:化療誘發性貧血

  • 摘要整理
  • 疾病的背景情況
  • 資訊來源、分析方法
  • 市場預測
  • 流行病學者的見解
  • 分析的優勢與限制

已上市藥物:化療誘發性貧血

  • 摘要整理
  • 產品概要
  • 鐵分補充品
  • 產品簡介:Aranesp
  • 產品簡介:Epogen

開發中產品:化療誘發性貧血

  • 摘要整理
  • 開發平台的趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC13706

The chemotherapy-induced anemia (CIA) market is expected to grow marginally due to a lack of novel therapies and a static disease population.

This report addresses the following questions:

  • How have developments in cancer treatment impacted the CIA market?
  • What will the future look like for erythropoiesis-stimulating agents (ESAs) in the CIA market, given their current contraindications and the limitations that they present?
  • What will be the major driving factors in the CIA market moving forward?
  • What are the most important factors influencing prescribing trends?
  • Where are the current opportunities in CIA for drug developers?

TABLE OF CONTENTS

FORECAST: CHEMOTHERAPY-INDUCED ANEMIA

  • 1. Executive Summary
  • 2. Market Overview and Trends
  • 3. Market Definition and Methodolog
  • 4. Aranesp (darbepoetin alfa)
  • 5. DexFerrum (iron dextran)
  • 6. Epogen (epoetin alfa)
  • 6. Feraheme (ferumoxytol)
  • 7. Injectafer (ferric carboxymaltose)
  • 8. NeoRecormon (epoetin beta)
  • 9. Venofer (iron sucrose)
  • 10. Primary Research Methodology

TREATMENT: CHEMOTHERAPY-INDUCED ANEMIA

  • 11. Executive Summary
  • 12. Primary Research Methodology
  • 13. Disease Definition and Diagnosis
  • 14. Patient Segmentation
  • 15. Country Treatment Trees
  • 16. Current Treatment Options
  • 17. Prescribing Trends
  • 18. Unmet Needs in Chemotherapy-Induced Anemia

EPIDEMIOLOGY: CHEMOTHERAPY-INDUCED ANEMIA

  • 19. Executive Summary
  • 20. Disease Background
  • 21. Sources and Methodology
  • 22. Forecast
  • 23. Epidemiologist Insight
  • 24. Strengths and Limitations

MARKETED DRUGS: CHEMOTHERAPY-INDUCED ANEMIA

  • 25. Executive Summary
  • 26. Product Overview
  • 27. Iron Supplements
  • 28. Product profile: Aranesp
  • 29. Product profile: Epogen

PIPELINE: CHEMOTHERAPY-INDUCED ANEMIA

  • 30. Executive Summary
  • 31. Pipeline Trends
Back to Top